Literature DB >> 18080837

Radiation therapy in acromegaly.

Helen A Shih1, Jay S Loeffler.   

Abstract

Radiation therapy is generally not a primary treatment modality for growth hormone-secreting pituitary adenomas. However, in patients with acromegaly refractory to medical and/or surgical interventions, radiation can offer durable tumor control and often biochemical remission. Technique of radiation therapy delivery and dose vary by adenoma size and extrasellar extension. Radiation can be delivered in a single sitting by stereotactic radiosurgery or in fractionated form of smaller doses delivered over typically 5-6 weeks in 25-30 treatments. A brief overview of forms of radiation modalities is reviewed followed by discussion of the role for radiation therapy, rationale of delivery method, and potential adverse effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18080837     DOI: 10.1007/s11154-007-9065-x

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  36 in total

1.  Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas.

Authors:  K Kajiwara; K Saito; K Yoshikawa; S Kato; T Akimura; S Nomura; H Ishihara; M Suzuki
Journal:  Minim Invasive Neurosurg       Date:  2005-04

2.  Radiosurgery for growth hormone-producing pituitary adenomas.

Authors:  N Zhang; L Pan; E M Wang; J Z Dai; B J Wang; P W Cai
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

3.  The efficacy of conventional radiation therapy in the management of pituitary adenoma.

Authors:  R Sasaki; M Murakami; Y Okamoto; K Kono; E Yoden; T Nakajima; S Nabeshima; Y Kuroda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

4.  The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Vincenzo Esposito; Antonio Santoro; Francesca Solda; Patrizia Gargiulo; Guido Tamburrano; Riccardo Maurizi Enrici
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

5.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.

Authors:  Roberto Attanasio; Paolo Epaminonda; Enrico Motti; Enrico Giugni; Laura Ventrella; Renato Cozzi; Mario Farabola; Paola Loli; Paolo Beck-Peccoz; Maura Arosio
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

6.  Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Authors:  J Ayuk; R N Clayton; G Holder; M C Sheppard; P M Stewart; A S Bates
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Low-dose pituitary irradiation for acromegaly.

Authors:  M D Littley; S M Shalet; R Swindell; C G Beardwell; M L Sutton
Journal:  Clin Endocrinol (Oxf)       Date:  1990-02       Impact factor: 3.478

8.  Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas.

Authors:  M Mitsumori; D C Shrieve; E Alexander; U B Kaiser; G E Richardson; P M Black; J S Loeffler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-10-01       Impact factor: 7.038

9.  Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk.

Authors:  R W Tsang; N J Laperriere; W J Simpson; J Brierley; T Panzarella; H S Smyth
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

10.  Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission.

Authors:  Bruce E Pollock; Jeffrey T Jacob; Paul D Brown; Todd B Nippoldt
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

View more
  2 in total

Review 1.  Octreotide-Resistant Acromegaly: Challenges and Solutions.

Authors:  Giuliana Corica; Marco Ceraudo; Claudia Campana; Federica Nista; Francesco Cocchiara; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Diego Ferone; Federico Gatto
Journal:  Ther Clin Risk Manag       Date:  2020-05-05       Impact factor: 2.423

2.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Authors:  Roberto Salvatori; Lisa B Nachtigall; David M Cook; Vivien Bonert; Mark E Molitch; Sandra Blethen; Stephen Chang
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.